Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Sep 30, 2019
Posted in: Investor updates

Home » Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Sep 30, 2019
Posted in: Investor updates

Imagion Biosystems Limited has given notice under section 708A(5)(e) of the Corporations Act 2001.
Read the notice.

The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging

October 17, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

September 4, 2026

Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

June 3, 2026

Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)

Transforming medical imaging for early disease detection

We’re on a mission to make cancer more detectable.

Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Notice Pursuant to Section 708A(5)(e) of the Corporations Act

Related Articles

The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging

The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials

Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

Transforming medical imaging for early disease detection

About Imagion Biosystems

Contact us

Join our email list